Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption

Cancer Research

Volumn 74, Issue 21, 2014, Pages 5948-5954

  Chan, Manuel ^a   Gravel, Michel ^a   Bramoullé, Alexandre ^a   Bridon, Gaëlle ^a,b   Avizonis, Daina ^a,b   Shore, Gordon C ^a   Roulston, Anne ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYURIDINE TRIPHOSPHATE PYROPHOSPHATASE; DIHYDROFOLATE REDUCTASE; GLYCOSYLTRANSFERASE INHIBITOR; GMX 1777; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEMETREXED; UNCLASSIFIED DRUG; 1-(2-(2-(2-(2-METHOXYETHOXY)ETHOXY)ETHOXY)ETHOXYCARBONYLOXYMETHYL)-4-(N'-CYANO-N''-(6-(4-CHLOROPHENOXY)HEXYL)-N-GUANIDINO)PYRIDINIUM; CYTOKINE; GLUTAMIC ACID DERIVATIVE; GUANIDINE DERIVATIVE; GUANINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; DHFR GENE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG SENSITIZATION; DUT GENE; ENZYME ACTIVATION; EXCISION REPAIR; FEMALE; GENE SILENCING; IC50; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER CELL LINE; MONOTHERAPY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DNA REPAIR; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYTOKINES; DNA REPAIR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANIDINES; GUANINE; HUMANS; MICE; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; POLY(ADP-RIBOSE) POLYMERASES; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84909620040     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0809     Document Type: Article

References (20)

1. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004;279:50754-63.
2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
3. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010;31:194-223.
4. Watson M, Roulston A, Belec L, Billot X, Marcellus R, Bedard D, et al. The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol Cell Biol 2009;29: 5872-88.
5. Beauparlant P, Bedard D, Bernier C, Chan H, Gilbert K, Goulet D, et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs 2009;20:346-54.
6. Binderup E, Bjorkling F, Hjarnaa PV, Latini S, Baltzer B, Carlsen M, et al. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorg Med Chem Lett 2005;15:2491-4.
7. Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, et al. Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+biosynthesis and base excision repair. Cancer Res 2011; 71:2308-17.
8. Kato H, Ito E, Shi W, Alajez NM, Yue S, Lee C, et al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res 2010;16:898-911.
9. Montecucco F, Cea M, Bauer I, Soncini D, Caffa I, Lasiglie D, et al. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets 2013;14:637-43.
10. Travelli C, Drago V, Maldi E, Kaludercic N, Galli U, Boldorini R, et al. Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells. J Pharmacol Exp Ther 2011;338: 829-40.
11. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-17.
12. Chou TC, Talalay P. Analysis of combined drug effects-a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
13. Weeks LD, Fu P, Gerson SL. Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. Mol Cancer Ther 2013;12:2248-60.
14. Barnes DE, Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet 2004; 38:445-76.
15. Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010; 39:8-24.
16. Pogrebniak A, Schemainda I, Azzam K, Pelka-Fleischer R, Nussler V, Hasmann M. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006;11:313-21.
17. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-and ageinduced diabetes in mice. Cell Metab 2011;14:528-36.
18. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-91.
19. Bulgar AD, Weeks LD, Miao Y, Yang S, Xu Y, Guo C, et al. Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis 2012;3:e252.
20. Mortusewicz O, Ame JC, Schreiber V, Leonhardt H. Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 2007;35:7665-75.